Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x. a x. 46/2008 Sb. x. x. a xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx úmluvě xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx zahraničních věcí xxxxxxx, xx xxx 11. listopadu 2013 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.¹⁾

X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. ledna 2014 x xxxxx xxxx vstoupilo v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx xxxxxx od 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Anglické xxxxx Přílohy I x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.

¹⁾ Xxxxxxxxxxx xxxxxx proti xxxxxxx ve sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. ledna 2014

XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2014

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x X3.

XXXXX X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

ZAKÁZANÉ LÁTKY

S0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu a xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx úřadem (xxxx. xxxxxx x xxxxxxxxxxxx xxxx klinickém xxxxxx výzkumu nebo xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, látky xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); bolasteron; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; methandriol; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (androst-4-en-3,17-dion), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx skupiny xxxx xxxxx:

* "exogenní" xx vztahuje k xxxxx, xxxxxx tělo xxxxxxxx přirozeně xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx tělo xxxxxxxx xxxxxxxxx produkuje.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx hormon (XX) x xxxxxx uvolňující xxxxxxx u mužů;

3. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (GH) x xxxx xxxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx xxxx zakázány xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx faktory (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), mechanické xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x vaskulárně-endoteliární růstový xxxxxx (VEGF), stejně xxxx jakékoliv xxxx xxxxxxx faktory xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x vaziva, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx;

x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx beta-2 agonisté, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx isomerů (xxxx. x- x l-), xxxx zakázáni xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů za 24 xxxxx), xxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx podaná xxxxx 54 mikrogramů xx 24 hodin) x xxxxxxxxxxx, pokud xxxx xxxxxx v xxxxxxxx x souladu x xxxxxxxxxxx léčebným xxxxxxx výrobce.

Přítomnost xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx za pozitivní xxxxxxxxxxx nález, pokud xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, anastrozol, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, xxxxxxxxx, letrozol, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, klomifen, ale xx s omezením xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale xx x omezením pouze xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Xxxxxxxx;

x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx AMP v xxxxxxxxxxx s XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) axis xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxx není zakázáno.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx, xxxxxxx (xxxx. tolvaptan) x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx xxxx xxxxx maskovací látkou xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx k té, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ A XXXXXXXX KOMPONENTAMI

Zakázané je xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx xx oběhového systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx náhražky xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (RSR13), ale xx s omezením xxxxx na xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Jakákoliv forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými způsoby.

M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx pokus x podvod, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Dopingové xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo úpravu (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx pouze xx xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml xx 6 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx nukleových kyselin xxxx jejich analogů;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx kategorií X0 xx S5 x X1 až X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx (xxxx. d- x l-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu v xxxxxxx xxxxxx xxxxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, amfepramon, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, mefenorex, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.

Stimulancium, xxxxx není xxxxxxxx xxxxxxx x tomto xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, benzfetamin, xxxxxxxxxxxxxxxxx, xxxxxxx***, etamivan, xxxxxxxxxxxxx, xxxxxxxxx, famprofazon, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxx (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx xxxxxxx (xxxx. mefedron, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, metylendioxymetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxx), pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx moči.

*** Efedrin x methylefedrin jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Lokální xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, xxxx xxxxxxxx) nebo jeho xxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx není xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx v xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, oxykodon, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. hašiš, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx", JWH018, XXX073 x XX-210) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

LÁTKY XXXXXXXX X URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x krvi 0.10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. BETA-BLOKÁTORY

Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX) (zakázané xxxx Xxxx xxxxxx)

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, a xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxx (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, propranolol, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

Informace

Právní předpis x. 47/2014 Xx. m. x. nabyl účinnosti xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx derogační změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.